![Jeffery S. Loutit](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffery S. Loutit
No más puestos en curso
Historial de carrera de Jeffery S. Loutit
Antiguos cargos conocidos de Jeffery S. Loutit.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Rempex Pharmaceuticals, Inc.
![]() Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | 01/11/2011 | 01/12/2013 |
Fundador | 01/11/2011 | 01/12/2013 | |
INTERMUNE INC | Corporate Officer/Principal | - | - |
Stanford University | Corporate Officer/Principal | - | - |
MPEX Pharmaceuticals, Inc.
![]() MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | - | - |
Formación de Jeffery S. Loutit.
University of Otago | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Nueva Zelanda | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
MPEX Pharmaceuticals, Inc.
![]() MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
InterMune, Inc.
![]() InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Rempex Pharmaceuticals, Inc.
![]() Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffery S. Loutit
- Experiencia